NCT00099788View on ClinicalTrials.gov

Metabolic Efficiency With Ranolazine for Less Ischemia in Non-ST Elevation Acute Coronary Syndromes

PHASE3CompletedINTERVENTIONAL
Enrollment

6,560

Participants

Timeline

Start Date

October 31, 2004

Primary Completion Date

February 28, 2007

Study Completion Date

February 28, 2007

Conditions
Myocardial Ischemia
Interventions
DRUG

Ranolazine

IV to oral transition.

DRUG

Placebo

IV to oral transition.

Trial Locations (1)

02115

The TIMI Study Group, Boston

Sponsors

Lead Sponsor

Gilead Sciences
All Listed Sponsors
collaborator

The TIMI Study Group

OTHER

lead

Gilead Sciences

INDUSTRY

NCT00099788 - Metabolic Efficiency With Ranolazine for Less Ischemia in Non-ST Elevation Acute Coronary Syndromes | Biotech Hunter | Biotech Hunter